VIDEO: Combination therapy could ‘challenge the paradigm’ of relapsed/refractory DLBCL care

In this video, Paolo Strati, MD, discusses the potential of bispecific antibody and antibody-drug conjugate combination therapy for relapsed or refractory diffuse large B-cell lymphoma, based on initial results from the LOTIS-7 trial.The trial was presented at Society of Hematologic Oncology’s Annual Meeting.